Technology appraisal (TA) Date of TA Adherence of local formulary to NICE Release Included on the Trust Formulary for this Reason provided if "No" indication Yes OR No 2018-19 27/03/2019 TA572 - Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes Yes 20/03/2019 TA571 - Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib Yes 20/03/2019 TA570 - Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma Terminated appraisal of the head and neck after platinum-based chemotherapy (terminated appraisal) No 20/03/2019 TA569 - Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer Yes 13/03/2019 TA568 - Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) No Terminated appraisal 13/03/2019 TA567 - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell Not applicable to CWFT - Condition not lymphoma after 2 or more systemic therapies No treated at CWFT 07/03/2019 TA566 - Cochlear implants for children and adults with severe to profound deafness No Not applicable - Medical device 06/03/2019 TA565 - Benralizumab for treating severe eosinophilic asthma Yes 27/02/2019 TA564 - Dabrafenib with trametinib for treating advanced metastatic BRAF V600E Terminated appraisal mutation-positive non-small-cell lung cancer (terminated appraisal) No 27/02/2019 TA563 - Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer Yes 27/02/2019 TA562 - Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma Yes 27/02/2019 TA561 - Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia Yes 20/02/2019 TA560 - Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first Terminated appraisal recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) No 23/01/2019 TA559 - Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary Not applicable to CWFT - Condition not mediastinal large B-cell lymphoma after 2 or more systemic therapies No treated at CWFT 23/01/2019 TA558 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease Yes 10/01/2019 TA557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Yes 09/01/2019 TA556 - Darvadstrocel for treating complex perianal fistulas in Crohn’s disease No Not recommended 09/01/2019 Not applicable to CWFT - Condition not TA555 - Regorafenib for previously treated advanced hepatocellular carcinoma No treated at CWFT 21/12/2018 TA554 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic Not applicable to CWFT - Condition not leukaemia in people aged up to 25 years No treated at CWFT 19/12/2018 TA553 - Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence Yes 19/12/2018 TA552 - Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia Yes 19/12/2018 Not applicable to CWFT - Condition not TA551- Lenvatinib for untreated advanced hepatocellular carcinoma No treated at CWFT 12/12/2018 TA550 - Vandetanib for treating medullary thyroid cancer No Not recommended 05/12/2018 TA549 - Denosumab for preventing skeletal-related events in multiple myeloma Terminated appraisal (terminated appraisal) No 05/12/2018 TA548 - Decitabine for untreated acute myeloid leukaemia (terminated appraisal) No Terminated appraisal 28/11/2018 TA547 - Tofacitinib for moderately to severely active ulcerative colitis Yes 21/11/2018 TA546 - Padeliporfin for untreated localised prostate cancer No Not recommended 14/11/2018 TA545 - Gemtuzumab ozogamicin for untreated acute myeloid leukaemia Yes 17/10/2018 TA544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma Yes 03/10/2018 TA543 - Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs Yes 03/10/2018 TA542 - Cabozantinib for untreated advanced renal cell carcinoma Yes 19/09/2018 TA541 - Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute Not applicable to CWFT - Condition not lymphoblastic leukaemia No treated at CWFT 03/09/2018 TA540 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma Yes 29/08/2018 TA539 - Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic Not applicable to CWFT - Condition not neuroendocrine tumours No treated at CWFT 22/08/2018 Not applicable to CWFT - Condition not TA538 - Dinutuximab beta for treating neuroblastoma No treated at CWFT 08/08/2018 TA537 - Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs Yes 08/08/2018 TA536 - Alectinib for untreated ALK-positive advanced non-small-cell lung cancer Yes 08/08/2018 TA535 - Lenvatinib and sorafenib for treating differentiated thyroid cancer after Not applicable to CWFT - Condition not radioactive iodine No treated at CWFT 01/08/2018 TA534 - Dupilumab for treating moderate to severe atopic dermatitis Yes 25/07/2018 Not applicable to CWFT - Specialist TA533 - Ocrelizumab for treating relapsing–remitting multiple sclerosis No Centres only and CWFT is not a commissioning Centre 18/07/2018 TA532 - Cenegermin for treating neurotrophic keratitis No Not recommended 18/07/2018 TA531 - Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer Yes 04/07/2018 TA530 - Nivolumab for treating locally advanced unresectable or metastatic urothelial Not recommended cancer after platinum-containing chemotherapy No 04/07/2018 TA529 - Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer Yes 04/07/2018 TA528 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, Not applicable to CWFT - Condition not fallopian tube and peritoneal cancer No treated at CWFT 27/06/2018 TA527 - Beta interferons and glatiramer acetate for treating multiple sclerosis Yes 13/06/2018 Not applicable to CWFT - Condition not TA526 - Arsenic trioxide for treating acute promyelocytic leukaemia No treated at CWFT 13/06/2018 TA525 - Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy Yes 13/06/2018 TA524 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma Yes 13/06/2018 Not applicable to CWFT - Specialist TA523 - Midostaurin for untreated acute myeloid leukaemia No Centres only and CWFT is not a commissioning Centre 13/06/2018 TA522 - Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable Yes 13/06/2018 TA521 - Guselkumab for treating moderate to severe plaque psoriasis Yes 16/05/2018 TA520 - Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy Yes 25/04/2018 TA519 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy Yes 18/04/2018 Not applicable to CWFT - Specialist TA518 - Tocilizumab for treating giant cell arteritis No Centres only and CWFT is not a commissioning Centre 11/04/2018 TA517 - Avelumab for treating metastatic Merkel cell carcinoma Yes.